In a nutshell This study evaluated the effect of brain metastases (BMs) status on immunotherapy effectiveness in patients with advanced lung cancer (LC). The data showed that the effectiveness of immunotherapy was similar in patients with or without BMs. Some background In 20-40% of patients with advanced LC, cancer spreads from the lung to the brain...
Read More
In a nutshell This study evaluated whether patients with unresectable non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from first-line treatment with tyrosine kinase inhibitor (TKI) therapy. The data showed that TKIs could be a good option for these patients. Some background NSCLC is the most common form of lung cancer....
Read More
In a nutshell This study investigated the optimal time interval between chemoradiotherapy (CRT) and surgery and its impact on survival outcomes in patients with locally advanced (LA) non-small-cell lung cancer (NSCLC). The data showed that surgery within 7 weeks after CRT was associated with improved survival outcomes in these patients. Some...
Read More
In a nutshell This study evaluated the effectiveness of immune checkpoint inhibitors (ICI) versus chemotherapy in patients with non-small cell lung cancer (NSCLC) andy brain metastases (BM). The data showed that the effectiveness of ICIs was similar in patients with no BM symptoms and/or treated BMs. For patients with BMs, ICI combination therapy was...
Read More
In a nutshell This study investigated the effectiveness and safety outcomes of nimotuzumab (Theraloc) combined with chemoradiotherapy (CRT) for the treatment of patients with locally advanced squamous non-small cell lung cancer (SqNSCLC). The data showed that nimotuzumab plus CRT had similar survival outcomes compared to CRT alone, but with a lower...
Read More
In a nutshell This study compared the effectiveness and safety outcomes of atezolizumab (Tecentriq) alone or with chemotherapy (CT) for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). The data showed that atezolizumab alone might be a better treatment option than atezolizumab plus CT for these patients. Some...
Read More
In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including small cell lung cancer, that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial is...
Read More
In a nutshell This article compared the safety and effectiveness of PD-L1/PD-1 immunotherapies (IT) for non-small cell lung cancer (NSCLC). The authors found that in the first-line setting, the most effective treatments for PD-L1 positive NSCLC were atezolizumab (Tecentriq), pembrolizumab (Keytruda)/chemotherapy (CT) combination, and nivolumab...
Read More
In a nutshell This study investigated the safety and effectiveness of afatinib (Gilotrif) in patients with non-small cell lung cancer (NSCLC) who have not previously received EGFR tyrosine kinase inhibitors (TKIs). Data showed that afatinib was well tolerated and improved the outcomes of these patients. Some background NSCLC...
Read More
In a nutshell This study investigated the effectiveness and safety outcomes of nivolumab (Opdivo) in combination with carboplatin (C; Paraplatin) and paclitaxel (P; Taxol) plus bevacizumab (B; Avastin) as first-line treatment for patients with advanced non-squamous non-small cell lung cancer (NSCLC). The data showed that nivolumab plus BCP...
Read More
In a nutshell This study looked at the effectiveness selpercatinib (Retevmo) for the treatment of patients with RET fusion-positive non-small cell lung cancer (NSCLC) that has spread to the brain. The authors found that selpercatinib was effective in these patients. Some background RET mutations are genetic abnormalities that can cause some...
Read More
In a nutshell This analysis was carried out to assess the outcomes of patients who underwent surgery only or surgery and chemotherapy (CT) for limited-stage small-cell lung cancer (LS-SCLC). The authors found that surgery plus CT resulted in better outcomes compared to surgery alone. Some background SCLC is an aggressive type of...
Read More
